back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-04-17 20:30 Tx date 2024-04-16 |
$WOLF
Grey Wolf Animal Health Corp. (formerly Magen Ventures I Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$14,600
+20,000 vol $0.73 each |
235,000 | |
| Filed 2022-11-16 18:23 Tx date 2022-11-15 |
$MAGNP
Grey Wolf Animal Health Corp. (formerly Magen Ventures I Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
215,000 | ||
| Filed 2022-11-16 18:22 Tx date 2022-11-15 |
$MAGNP
Grey Wolf Animal Health Corp. (formerly Magen Ventures I Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
232,162 | ||
| Filed 2022-05-19 21:55 Tx date 2022-05-18 |
$MRV
Nuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Deferred Share Unit Plan (DSU)
56 - Grant of rights
|
+12,113 vol |
19,793 | |
| Filed 2021-05-21 12:13 Tx date 2021-05-20 |
$MRV
Nuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Deferred Share Unit Plan (DSU)
56 - Grant of rights
|
+7,680 vol |
7,680 | |
| Filed 2021-05-21 12:12 Tx date 2017-05-11 |
$MRV
Nuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Deferred Share Unit Plan (DSU)
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-07-02 09:51 Tx date 2020-06-30 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,530
+7,000 vol $0.79 each |
75,000 | |
| Filed 2020-06-11 13:58 Tx date 2020-06-10 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,340
+3,000 vol $0.78 each |
68,000 | |
| Filed 2020-06-10 14:07 Tx date 2020-03-13 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,120
+2,000 vol $0.56 each |
36,000 | |
| Filed 2020-06-10 10:34 Tx date 2020-06-05 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$6,304
+8,000 vol $0.79 each |
63,000 | |
| Filed 2020-05-19 15:04 Tx date 2020-05-14 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,650
+5,000 vol $0.73 each |
55,000 | |
| Filed 2020-05-19 15:02 Tx date 2020-05-14 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,000
+10,000 vol $0.70 each |
50,000 | |
| Filed 2020-05-14 13:54 Tx date 2020-05-13 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+7,000 vol |
110,655 | |
| Filed 2020-03-25 18:12 Tx date 2020-03-25 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,200
+2,000 vol $0.60 each |
40,000 | |
| Filed 2020-03-25 18:12 Tx date 2020-03-25 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,320
+4,000 vol $0.58 each |
38,000 | |
| Filed 2020-03-06 16:19 Tx date 2020-03-05 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$840.00
+1,000 vol $0.84 each |
34,000 | |
| Filed 2020-03-06 16:18 Tx date 2020-03-05 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,075
+2,500 vol $0.83 each |
33,000 | |
| Filed 2020-03-06 16:18 Tx date 2020-03-05 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,645
+4,500 vol $0.81 each |
30,500 | |
| Filed 2020-03-06 16:16 Tx date 2020-03-05 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,600
+2,000 vol $0.80 each |
26,000 | |
| Filed 2020-03-06 16:10 Tx date 2020-03-04 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,880
+4,000 vol $0.97 each |
24,000 | |
| Filed 2020-03-04 16:18 Tx date 2020-03-02 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$7,200
+8,000 vol $0.90 each |
20,000 | |
| Filed 2020-03-02 13:43 Tx date 2020-02-28 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,480
+4,000 vol $0.87 each |
12,000 | |
| Filed 2020-03-02 13:42 Tx date 2020-02-28 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,520
+4,000 vol $0.88 each |
8,000 | |
| Filed 2020-03-02 13:42 Tx date 2020-02-28 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,880
+2,000 vol $0.94 each |
4,000 | |
| Filed 2020-03-02 13:41 Tx date 2020-02-27 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,780
+2,000 vol $0.89 each |
2,000 | |
| Filed 2020-03-02 13:40 Tx date 2017-05-11 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-10-11 14:55 Tx date 2019-10-07 |
$OH
CannaRoyalty Corp. dba Origin House |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Restricted Share Unit
56 - Grant of rights
|
$59,100
+10,000 vol $5.91 each |
110,000 | |
| Filed 2019-01-10 Tx date 2019-01-10 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
103,655 | |
| Filed 2019-01-09 Tx date 2019-01-04 |
$OH
CannaRoyalty Corp. dba Origin House |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-26,600
-3,800 vol $7.00 each |
22,867 | |
| Filed 2019-01-01 Tx date 2018-12-28 |
$OH
CannaRoyalty Corp. dba Origin House |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-32,250
-5,000 vol $6.45 each |
26,667 | |
| Filed 2018-12-20 Tx date 2018-12-19 |
$OH
CannaRoyalty Corp. dba Origin House |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-32,500
-5,000 vol $6.50 each |
31,667 | |
| Filed 2018-12-18 Tx date 2018-12-14 |
$OH
CannaRoyalty Corp. dba Origin House |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-60,500
-10,000 vol $6.05 each |
51,667 | |
| Filed 2018-12-18 Tx date 2018-12-14 |
$OH
CannaRoyalty Corp. dba Origin House |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-30,500
-5,000 vol $6.10 each |
46,667 | |
| Filed 2018-12-18 Tx date 2018-12-17 |
$OH
CannaRoyalty Corp. dba Origin House |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-63,510
-10,000 vol $6.35 each |
36,667 | |
| Filed 2018-12-18 Tx date 2018-12-12 |
$OH
CannaRoyalty Corp. dba Origin House |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-32,580
-5,000 vol $6.52 each |
61,667 | |
| Filed 2018-06-25 Tx date 2018-06-20 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
$-28,154.25
-13,095 vol $2.15 each |
207,736 | |
| Filed 2018-05-16 Tx date 2018-05-11 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
$-3,770.25
-7,500 vol $0.50 each |
0 | |
| Filed 2018-05-16 Tx date 2018-05-11 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$3,770
+7,500 vol $0.50 each |
601,594 | |
| Filed 2018-03-28 Tx date 2018-03-28 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+7,000 vol |
28,655 | |
| Filed 2018-03-12 Tx date 2016-12-05 |
$CRZ
CannaRoyalty Corp. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-03-12 Tx date 2017-12-29 |
$CRZ
CannaRoyalty Corp. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
200,000 | |
| Filed 2018-03-12 Tx date 2016-12-05 |
$CRZ
CannaRoyalty Corp. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Restricted Share Unit
00 - Opening Balance-Initial SEDI Report
|
100,000 | ||
| Filed 2018-02-28 Tx date 2018-02-27 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
-45,469 vol |
0 | |
| Filed 2017-05-23 Tx date 2017-05-19 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+16,221 vol |
16,221 | |
| Filed 2017-05-23 Tx date 2017-05-11 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-05-23 Tx date 2017-05-19 |
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.) |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+5,434 vol |
21,655 | |
| Filed 2017-05-12 Tx date 2017-05-11 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+7,500 vol |
7,500 | |
| Filed 2017-05-12 Tx date 2017-05-11 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+15,000 vol |
220,831 | |
| Filed 2017-05-12 Tx date 2017-05-03 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$10,575
+7,500 vol $1.41 each |
594,094 | |
| Filed 2017-05-12 Tx date 2017-05-03 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
$-10,575
-7,500 vol $1.41 each |
0 | |
| Filed 2017-04-13 Tx date 2016-02-05 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
45,469 | ||
| Filed 2017-04-13 Tx date 2016-02-05 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Holder: Spouse (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
600,188 | ||
| Filed 2017-02-02 Tx date 2016-12-05 |
$CRZ
CannaRoyalty Corp. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
66,667 | ||
| Filed 2016-11-30 Tx date 2016-11-28 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-93,000
-20,000 vol $4.65 each |
586,594 | |
| Filed 2016-11-30 Tx date 2016-11-29 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-410,729.76
-104,778 vol $3.92 each |
205,831 | |
| Filed 2016-11-30 Tx date 2016-11-28 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-78,400
-20,000 vol $3.92 each |
310,609 | |
| Filed 2016-11-30 Tx date 2016-11-29 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-523,146.0762
-104,778 vol $4.99 each |
586,594 | |
| Filed 2016-11-30 Tx date 2016-11-29 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$410,729
+104,778 vol $3.92 each |
691,372 | |
| Filed 2016-11-30 Tx date 2016-11-28 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$78,400
+20,000 vol $3.92 each |
606,594 | |
| Filed 2016-09-20 Tx date 2016-09-15 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-420,000
-75,000 vol $5.60 each |
661,594 | |
| Filed 2016-09-20 Tx date 2016-09-15 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-453,217.50
-75,000 vol $6.04 each |
586,594 | |
| Filed 2016-06-20 Tx date 2016-02-05 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-06-20 Tx date 2016-06-16 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+15,000 vol |
330,609 | |
| Filed 2016-06-20 Tx date 2016-06-16 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+7,500 vol |
7,500 | |
| Filed 2016-02-10 Tx date 2016-02-05 |
$TRX
Tribute Pharmaceuticals Canada Inc. (formerly Stellar Pharmaceuticals Inc.) |
Harris, Robert Paul
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-2,169,135 vol |
0 | |
| Filed 2016-02-10 Tx date 2016-02-05 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
315,609 | ||
| Filed 2016-02-10 Tx date 2016-02-05 |
$ARZ
Aralez Pharmaceuticals Inc. |
Harris, Robert Paul
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
736,594 | ||
| Filed 2016-02-05 Tx date 2016-02-05 |
$TRX
Tribute Pharmaceuticals Canada Inc. (formerly Stellar Pharmaceuticals Inc.) |
Harris, Robert Paul
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-5,062,500 vol |
0 |